Assessment of Neonatal Hyperbilirubinemia by NeoprediX B.1 Algorithm
NCT ID: NCT05121311
Last Updated: 2022-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
455 participants
OBSERVATIONAL
2021-08-09
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction of Neonatal Hyperbilirubinemia
NCT01109277
Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants
NCT03195998
Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
NCT02691156
Reliability of Transcutaneous Bilirubin Measurement According to the Skin Colour of Newborns
NCT07315126
Transcutaneous Bilirubinometry in Neonates
NCT01422655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to evaluate the precision of the NeoprediX B1 algorithm. This algorithm predicts bilirubin values 24-48h into the future based on preceding values and some clinical variables. Five different scenarios will be explored, differing in the type, number and timepoints of measurements used for the prediction as well as the timepoint that is to be predicted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Newborns under bilirubin monitoring
Bilirubin monitoring according to standard of care of the participating center
NeoprediX B1 algorithm
Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NeoprediX B1 algorithm
Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* gestational age at birth ≥ 34+0/7 weeks
Exclusion Criteria
* Gestational age at birth \> 42+6/7 weeks
* Genetically defined syndrome
* Severe congenital malformation adversely affecting life expectancy or admission for a priori planned palliative care
* Parents not fluent in German
72 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center for Pediatric Clinical Studies (CPCS)
UNKNOWN
NeoPredix AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Axel Franz, Prof.
Role: PRINCIPAL_INVESTIGATOR
University Children's Hospital Tübingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KUNO Kinderklinik St. Hedwig
Regensburg, , Germany
University Children's Hospital
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
507/2021B02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.